MDxHealth is a multinational healthcare company that provides actionable epigenetic information to personalize the diagnosis and treatment of cancer.
The company’s tests are based on proprietary gene methylation (epigenetic) technology and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy.
An overview of the most recent information about MDxHealth can be found in the company’s periodic corporate presentation slides and can be download here.
Corporate Governance Charter
MDxHealth attaches great value to corporate governance practices. On September 7, 2011, our board of directors approved the current version of MDxHealth’s Corporate Governance Charter. The Charter has been drafted in accordance with the principles and the provisions of the Belgian Corporate Governance Code 2009 issued on March 12, 2009 by the Corporate Governance Committee.
The full text of MDxHealth’s Corporate Governance Charter can be downloaded here.
MDxHealth is listed on the Euronext under the ticker symbol MDXH.
MDxHealth has been listed on Euronext since June 2006. There is only one class of shares in the company (common shares) and all shares have the same rights and voting representation. There are no other financial instruments issued by the company other than stock options issued to employees, directors, and some consultants.
Code of Ethics
The full text of MDxHealth’s Code of Ethics can be downloaded here.
As a listed company, MDxHealth must comply with rules governing insider trading. The company’s dealing code can be found here.
Share capital history
The history of the share capital issuance since the inception of the company can be found here:
Transparency Declarations of the largest shareholders
The table below provides an overview of the shareholders that filed a notification with MDxHealth SA pursuant to applicable transparency disclosure rules. Although the applicable transparency disclosure rules require that a disclosure must be made by each person passing or falling under one of the relevant thresholds, it is possible that the information below in relation to a shareholder is no longer up-to-date. The percentages of voting rights mentioned in the table have been calculated on the basis of the currently outstanding shares.
|SHAREHOLDER (OR PARTY REPRESENTING SHAREHOLDERS)||MVM PARTNERS LLP||BIOVEST COMM.VA||VALIANCE ASSET MANAGEMENT||SCORPIAUX BVBA|
|% OF OUTSTANDING SHARES||22.23%||13.99%||12.30%||4.26%|
|SITUATION AS OF||May 15,2020||June 26,2015||May 15,2020||May 15,2020|
|NOTIFICATION RECEIVED||May 18,2020||July 1,2015||May 21,2020||June 2,2020|
|NOTIFICATION FORM||Click here to view form||Click here to view form||Click here to view form||Click here to view form|
*Percentage calculated as per the date of the relevant transaction and taking into account the total number of outstanding shares as per such date
Each natural or legal person acquiring or transferring MDxHealth’s shares is required to notify MDxHealth and the Financial Services and Markets Authority (FSMA) each time their shareholding crosses a threshold of three percent (3%) of the total number of outstanding shares (the denominator). Such notification is also required each time, as a result of an acquisition or transfer a threshold of five percent (5%) and a multiple of five percent (5%) is crossed. Complete information regarding this requirement is found in Article 14 of MDxHealth’s articles of association.
The transparency notifications should be reported within 5 business days of crossing the threshold by following the procedures outlined on the FSMA website found here.
Special and Extraordinary Shareholders' Meeting (July 30, 2020)
Minutes of the Extraordinary General Meeting of the Shareholders July 30, 2020: Français
Proxy Form: English/Français
Voting by Mail Form: English/Français
Previous Shareholder Meetings
The financial service for the shares of the company is provided in Belgium by ING. Shareholders should inform themselves about the costs that other financial intermediaries may charge in connection with paying agency services.